Abstract 1587P
Background
The treatment and survival associated with multiple cancers has dramatically improved over the past decade with therapeutic advances. While print and broadcast media often report on cancer, it is unknown how movies depict cancer, treatment, or outcomes. Given that film may influence and shape public opinion, and potential willingness to seek out cancer treatment, we evaluated the portrayal of cancer in movies.
Methods
We searched for movies released between 2010 and 2020 using IMDb.com with search references for cancer in keywords. We excluded non-English language movies to avoid error in translation. We viewed and coded movies to include character’s role, diagnosis, curability, treatment, race/ethnicity, and gender. Per institutional policies, the study was not submitted for IRB approval because all data are publicly available.
Results
We identified 104 movies depicting cancer and oncologists between 2010 and 2020. A total of 108 characters with cancer were portrayed. Female characters were depicted more often (n = 60, 55.6%) than male characters (n = 48, 44.4%). The type of cancer was most often not specified in the movie (n = 40, 37%). The majority of characters were portrayed as having an incurable cancer (n = 70, 64.8%), while the curability of cancer was unknown in 21.3% of roles (n = 23). Only 13.9% of characters (n = 15) were depicted as having a curable cancer. The cancer-directed therapy was not specified or depicted for most characters (n = 37, 34.3%). When treatment was depicted or specified, chemotherapy was the most common treatment shown (n = 36, 33.3%). Two characters were depicted as choosing alternative medicine. Twelve characters were shown to choose forgoing cancer directed treatment. Zero characters (0%) were shown receiving immune checkpoint inhibitors or genomic-based therapies. Hospice or palliative care was discussed and offered for 8 characters (7.4%).
Conclusions
Most movies released from 2010 to 2020 with an oncology storyline do not contain granular details about cancer type or treatment. Most characters were portrayed as having an incurable malignancy. Chemotherapy was the most commonly depicted therapy while newer therapies were not depicted. The portrayal of oncology in recent English-language movies does not accurately reflect the reality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.J. Benjamin: Financial Interests, Advisory Board: Astellas, Eisai, Seagen; Financial Interests, Speaker’s Bureau: Merck; Financial Interests, Other: Merck. A. Rezazadeh Kalebasty: Financial Interests, Personal, Advisory Board, advisory board and speaker: Exelixis, Bayer, Pfizer, Genentech, EMD Serono; Financial Interests, Personal, Advisory Board, speaker and advisory board: AstraZeneca, Novartis, BMS; Financial Interests, Personal, Invited Speaker: Janssen, Astellas Medivation, Pfizer, Novartis, Genentech/Roche, Eisai, AstraZeneca, BMS, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/ Astellas, Myovant, Gilead Sciences; Financial Interests, Personal, Advisory Board: Gilead Sciences; Financial Interests, Institutional, Local PI: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, BMS, Eisai, Macrogenics, Astellas, Beyond Spring, Bioclin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizy, Arnivas, Navire, Point biopharma, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10